Emmanuel Caprais: Yes. And I would say, Vlad, that when you think about the past, obviously, maintaining pricing is important for us, while commodities are slowly declining. I think productivity has been has been a war machine in terms of productivity. And obviously, we continue to count on that. And then when you think about the other businesses out of friction, they’ve been also quite impacted by commodities inflation business like Axtone Steel, for instance, Wolverine as well. And so we’re really driving the recovery in those businesses to help us get back to that 20% margin target. That, as Luca was saying, may not be around that 3-year horizon, but more around the 5-year horizon.
Luca Savi: So Vlad, if you think about Axtone, I mean 25% of Axtone business disappeared overnight and that was a very good profitable Russia business. Now despite all of that, Axtone was profitable in the mid-single digit. But as you see now, they have to recover and have to rebuild with a different footprint with a different market.
Vlad Bystricky: Maybe just as a follow-up, Wanted to ask you a little about Habonim actually. That business seems to be performing quite well versus your expectations, and you highlighted how the business expanded IP’s valves portfolio. So could you talk about sort of your opportunity in VAVE and how you’re thinking about the potential to continue expanding your presence there either with Habonim or through incremental capital deployment in that end market?
Luca Savi: Thanks for your question, Vlad. That’s spot on. I think the VAVE is an area where we are investing and growing organically and inorganically. We have some very differentiated products with IP, with intellectual property that can be used in pharma and biopharma that happens when with some key accounts. And we keep on investing on that front. On an organic point of view, we have opportunities in the pipeline. So we will keep on investing also inorganically and as well as leverage the Habonim acquisition to expand more with — more with the Habonim happening products in North America. So all of that is happening. And there are some key markets where Habonim is strong. It might be cryogenic, pharma, hydrogen that we are penetrating more and more, that in terms of investment, in terms of opportunity for the future, M&A, et cetera.
When it comes to the results, it’s been a great acquisition. It’s been a very well-executed integration that was not so focused on the integration as much as value creation. And if you think about the multiples related to today is between 8% and 9%. So it was, as I said, a great deal and very well executed by Ilan and by Kasturi by the entire team.
Emmanuel Caprais: And I would add to this that as we had previewed when we acquired Habonim, it is also helping that acquisition is also helping us see things differently in the way we manage our existing engineered VAVE business. And so we’ve been driving a lot of the margin up in that business, which has participated in the margin expansion story also of IP. And I would say on that business, engineer Valves, which was the legacy business of ITT, we are seeing significant opportunities from the biopharm standpoint. So also in that regard, Habonim as well as our existing business are expected to grow significantly in 2023.
Operator: Our next question comes from the line of Jeff Hammond of KeyBanc Capital Markets.
Jeff Hammond : I think you gave some good color on the segment guidance for 1Q, but I’m just wondering like if you can rank order kind of confidence in the level of margin expansion for each of the segments or where you see the most and least.
